Non-Propagative Viral Vectors for IL-7 Delivery in Immune Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical solutions are inadequate for treating immune depression induced by sepsis, burn, trauma, major surgery, senescence, and coronavirus, leading to high mortality rates and a need for alternative therapies to restore immune function.
Innovation Solution
Development of non-propagative viral vectors encoding IL-7 polypeptides, which are administered to induce IL-7 production in situ, enhancing immune cell activation and survival, and improving immune function in patients with immune depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If blocking inflammation is used to suppress the host immune system response in sepsis, then the overwhelming immune response is reduced, but the immune system becomes overly suppressed leading to increased mortality
Solution Approach 1:
The patent changes the therapeutic parameter from broad immune suppression to targeted IL-7 supplementation. By specifically increasing IL-7 levels through viral vector delivery, the treatment restores T-cell and B-cell function without causing widespread immune suppression, thereby improving survival while avoiding the harmful effects of over-suppression
Solution Approach 2:
The patent introduces IL-7 as an intermediary molecule to mediate immune restoration. The viral vector delivers IL-7 which then acts as a mediator to stimulate T-cell and B-cell proliferation and activation, bridging the gap between immune suppression and immune overactivation without directly suppressing the immune system
2Duration of action of moving object
If non-propagative viral vectors are used to deliver IL-7, then IL-7 production is induced in situ with sustained effect, but the complexity of the treatment increases
Solution Approach 1:
The patent applies preliminary action by using the viral vector to pre-establish IL-7 production capacity within the patient's own cells. The vector delivers the IL-7 gene into host cells before the immune depression fully sets in or during early treatment, enabling the cells to produce IL-7 autonomously and sustainedly without requiring continuous external administration
Solution Approach 2:
The patent implements self-service by enabling the patient's own cells to produce IL-7 through the delivered genetic material. The modified cells autonomously synthesize and secrete IL-7 without continuous external intervention, making the treatment system self-sustaining and reducing the complexity of repeated administrations
Data Source
AI summary
The present invention is in the field of immunotherapy. The invention provides non-propagative viral vectors comprising a nucleic acid molecule encoding at least a polypeptide having an IL-7 activity, wherein said non-propagative viral vector is for use in the treatment of immune depression induced by sepsis, burn, trauma, major surgery, senescence and/or coronavirus.